Why IMU is a multi multi bagger, page-25697

I know we as humans have an ingrained tendency to speculate, particularly in matters pertaining to financial in nature.
However we only need to look at where we sit presently, which looks pretty damn good.
We will get futher data this year on most of our trials, safety is clearly not an issue, we already have signs of efficacy in early dosage in a particular cancer (Cholangiocarcinoma) and we have outstanding preclinical study results.
Yuman has declared that we are seeing in humans what was seen in animal studies, time will confirm what the optimum dosage will be.
We have money in the bank, even Mark Bouris was impressed with our ability to raise such high amounts, in a market not usually excited by Biotechnology companies.
The only disappointment and what seems to be for some the main concern is the shareprice, talk about 'not seeing the forest for the trees'.
I know this may seem for some, a zero sum game in that it could go through the roof or alternatively through the floor, however with so many shots on goal, we are derisked to a certain degree and we have some very intelligent sophisticated investers that are very patient and have much confidence in the Management of Imugene.
It's all very well to look to the future, let's not forget what is taking place right now.

DYOR opinion only